Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Rhea-AI Summary

Pasithea Therapeutics Corp. (NASDAQ: KTTA), a clinical-stage biotech company, will present at the H.C. Wainwright 26th Annual Global Investment Conference in New York City. The company is developing PAS-004, a next-generation macrocyclic MEK inhibitor for treating neurofibromatosis type 1 (NF1) and other cancer indications.

Key points:

• Presentation available online from 7:00 a.m. ET on September 9th, 2024
• Management to conduct 1x1 meetings from September 9-11, 2024
• Conference held at the Lotte New York Palace Hotel
• Registration available at https://hcwevents.com/annualconference/

SOUTH SAN FRANCISCO, Calif. and MIAMI, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”) a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1) and other cancer indications, today announced that members of its management team will deliver a company presentation at the H.C. Wainwright 26th Annual Global Investment Conference.

The conference will be held at the Lotte New York Palace Hotel in Midtown Manhattan, New York. Pasithea´s presentation will be available online for conference participants beginning at 7:00 a.m. Eastern Time on Monday, September 9th.

Management will also conduct 1x1 meetings in NYC from September 9^th through September 11th.

Registration and other information about the event can be found at https://hcwevents.com/annualconference/.

About Pasithea Therapeutics Corp.

Pasithea is a biotechnology company focused on the discovery, research and development of innovative treatments for central nervous system (CNS) disorders and RASopathies. With an experienced team of experts in the fields of neuroscience, translational medicine, and drug development, Pasithea is developing new molecular entities for the treatment of neurological disorders, including Neurofibromatosis type 1 (NF1), Solid Tumors, and Amyotrophic Lateral Sclerosis (ALS).

Forward Looking Statements

This press release contains statements that constitute “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include all statements, other than statements of historical fact, regarding the Company’s current views and assumptions with respect to future events regarding its business, as well as other statements with respect to the Company’s plans, assumptions, expectations, beliefs and objectives, the success of the Company’s current and future business strategies, product development, preclinical studies clinical studies, clinical and regulatory timelines, market opportunity, competitive position, business strategies, potential growth opportunities and other statements that are predictive in nature. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including factors set forth in the Company’s most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q and other filings made with the U.S. Securities and Exchange Commission (SEC). Thus, actual results could be materially different. The Company undertakes no obligation to update these statements whether as a result of new information, future events or otherwise, after the date of this release, except as required by law.

Pasithea Therapeutics Contact

Patrick Gaynes
Corporate Communications
pgaynes@pasithea.com

FAQ

When is Pasithea Therapeutics (KTTA) presenting at the H.C. Wainwright Global Investment Conference?

Pasithea Therapeutics (KTTA) will have its presentation available online starting at 7:00 a.m. Eastern Time on Monday, September 9th, 2024, at the H.C. Wainwright 26th Annual Global Investment Conference.

What is the main product Pasithea Therapeutics (KTTA) is developing?

Pasithea Therapeutics (KTTA) is developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1) and other cancer indications.

Where will the H.C. Wainwright 26th Annual Global Investment Conference be held?

The H.C. Wainwright 26th Annual Global Investment Conference will be held at the Lotte New York Palace Hotel in Midtown Manhattan, New York.

Will Pasithea Therapeutics (KTTA) management be available for meetings during the conference?

Yes, Pasithea Therapeutics (KTTA) management will conduct one-on-one meetings in New York City from September 9th through September 11th, 2024.